key: cord-1040715-mnkgp2j0
authors: Guijarro-Castro, C.; Rosón-González, M.; Abreu, A.; García-Arratibel, A.; Ochoa-Mulas, M.
title: Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases
date: 2020-08-31
journal: Neurología (English Edition)
DOI: 10.1016/j.nrleng.2020.06.002
sha: e17152b82d6f8a533babb913736e6fcd78bc4bc7
doc_id: 1040715
cord_uid: mnkgp2j0

nan

Dear Editor:

It was with great interest that we read the article by Velayos-Galán et al. 1 We would like to report a similar case of Guillain-Barré syndrome (GBS) that manifested after bilateral pneumonia due to SARS-CoV-2 infection, and analyse the data published on this entity.

On 4 May 2020, a 70-year-old man presented subacute weakness in all 4 limbs, which worsened over the following 5 days. Three weeks earlier, he had presented bilateral pneumonia due to SARS-CoV-2 infection: a chest CT scan showed ground-glass opacities in both lungs, and PCR results were positive for SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs. The patient was treated with oxygen therapy, hydroxychloroquine, azithromycin, ceftriaxone, and dexamethasone. The patient had no relevant medical history. His body temperature was 36.5 • C and baseline oxygen saturation was 99%. Pulmonary auscultation revealed no alterations. A neurological examination revealed asymmetrical weakness (Medical Research Council grade 4/5 in the right hand; 4+/5 in the left hand; 4/5 in the left leg, and 3+/5 in the right leg) and areflexia in the legs and feet. Two days after admission, symptoms worsened. Muscle strength was 4/5 in the arms and hands and 3/5 in the legs and feet. Light touch and pin prick distal sensitivity was decreased in distal regions.

Laboratory analysis at admission revealed lymphocytopaenia (0.52 × 10 3 cells/L; normal range: 1.1-3.2 × 10 3 cells/L) and thrombocytopaenia (113 × 10 3 cells/L; normal range: 125-300 × 10 3 cells/L). CSF analysis showed normal cell count (0 × 10 3 cells/L; normal range: 0-8 × 10 3 cells/L) and a slightly increased protein level (49 mg/dL; normal range: 8-43 mg/dL). Nerve conduction studies performed on day 6 revealed delayed distal latencies and absence of F waves in the early phase, in the context of mixed-type (axonal and demyelinating) acute motor polyneuropathy of moderate and symmetrical intensity in all 4 limbs, with associated axonal sensory involvement, loss of motor units, and signs of neurogenic involvement of the muscles analysed without acute denervation ( Table 1 ). The patient was diagnosed with GBS and started treatment on high-dose intravenous immunoglobulins (0.4 g/kg/day for 5 days) 8 hours after admission; symptoms improved on day 3 of treatment.

Upon discharge, 14 days after admission, he only presented mild weakness in the interosseous muscles of the hands (4+/5) and dorsiflexor muscles of both feet (4+/5), as well as generalised areflexia. The PCR results for SARS-CoV-2 at discharge were negative.

To our knowledge, 3 cases of concomitant GBS and SARS-CoV-2 infection with parainfectious profiles 1-3 and 13 cases of GBS subsequent to SARS-CoV-2 infection [4] [5] [6] [7] [8] [9] [10] [11] [12] have been reported to date ( Table 2 ). The favourable progression of most of the patients who presented GBS after the infection is noteworthy.

In our patient, the gradual progression of neurological symptoms resembles that observed with postinfectious aetiologies. Therefore, we suspect an association between acute polyneuropathy and SARS-CoV-2 infection. This association is supported by the fact that the patient observed home isolation for 21 days before neurological symptom onset, as well as the negative results for antiganglioside antibodies. However, the postinfectious onset, acute clinical course, and typical neurophysiological findings of GBS (mixed-type polyneuropathy of motor and sensory fibres), together with the absence of history of autoimmune, neoplastic, or neurological disease, suggest postinfectious aetiology. A significant limitation is the lack of availability of SARS-CoV-2 serology tests and CSF PCR tests at our centre. While our case is suggestive of a possible association between GBS and SARS-CoV-2 infection, further case reports with epidemiological data are needed to demonstrate a causal relationship. This case also underscores the need to consider possible neurological symptoms of SARS-CoV-2 infection.

The authors agree that there is a need for careful observation of neurological complications of SARS-CoV-2 infection.

The Spanish Society of Neurology is currently conducting a national observational study on neurological presentations and manifestations of COVID-19.

Emergency implementation of a teleneurology service at the neuromuscular diseases unit of Hospital Regional de Málaga during the SARS-CoV-2 pandemic ଝ Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2

Teleneurology was initially developed to provide care for complex, acute disorders in patients living in remote places, ଝ Please cite this article as: Romero-Imbroda J, Reyes-Garrido V, Ciano-Petersen NL, Serrano-Castro PJ. Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2. Neurología. 2020;35:415-417.

as was the case with telestroke. 1 However, in recent years its use has been expanded to treat other neurological diseases, and teleneurology has been gradually incorporated into routine outpatient follow-up. 2 Benefits include a reduction in time and travel costs for patients, improved access from remote areas, and perceived satisfaction among professionals and patients and their family members. Its limitations include the loss of traditional in-person relationships, the inability to perform a complete neurological examination, and neurologists' concerns about a possible loss of diagnostic accuracy. 3 We may distinguish 3 means of communication between neurologists and patients in teleneurology: telephone, audiovisual systems, and written consultation. 4 We propose the abbreviations t-consultation for telephone consultations, v-consultation for video consultations, and e-consultation 5 for written consultations.

Since the publication in Spain of Royal Decree 463/2020, 6 declaring the state of alarm that transferred management of the healthcare crisis caused by the SARS-CoV-2 coronavirus

Síndrome de Guillain-Barré asociado a infección por SARS-CoV-2

Guillain-Barré syndrome related to COVID-19 infection

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol

Guillain-Barré syndrome following COVID-19: new infection, old complication?

Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. Case reports

Covid-19 and Guillain-Barré syndrome: more than a coincidence! Rev Neurol (Paris)

Guillain-Barré syndrome as a complication of SARS-CoV-2 infection

Fatal Guillain-Barre syndrome after infection with SARS-CoV-2

Guillain-Barré syndrome associated with SARS-CoV-2 infection

COVID-19 may induce Guillain-Barré síndrome

Guillain Barre syndrome associated with COVID-19 infection: a case report

Guillain-Barré syndrome associated with SARS-CoV-2

del Grupo de Estudio de Humanidades e Historia de la Neurología de la SEN